# Linerixibat PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/linerixibat

> The next catalyst for linerixibat, sponsored by GSK plc (GSK), is its topline data readout, Oct 2028 to Jan 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | linerixibat |
| Codes | GSK2330672 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Cholestasis](https://sec-api.dev/indications/cholestasis), [Pruritus](https://sec-api.dev/indications/pruritus) |
| Modality |  |
| FDA designations | orphan, priority review |

## Timeline

### March 24, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-03-09, last confirmed 2026-03-09.
- SEC Form 8-K (accession 0001654954-26-002008): "Under the terms of the agreement, GSK will receive an upfront payment of $300 million, plus $100 million upon US FDA approval (expected prior to transaction closing, based on current PDUFA target approval date of 24 March 2026)." https://www.sec.gov/Archives/edgar/data/1131399/000165495426002008/a8361v.htm

### Sep to Dec 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Cholestasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04167358 (Linerixibat Long-term Safety, and Tolerability Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT04167358

### September 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Cholestasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04167358 (Linerixibat Long-term Safety, and Tolerability Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT04167358

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pruritus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07860710 (J-LINX: Japan LINerixibat eXtension Study): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07860710

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pruritus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07860710 (J-LINX: Japan LINerixibat eXtension Study): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-10-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07860710

## Same indication

- [Fexofenadine (loratadine if not available)](https://sec-api.dev/pdufa/fexofenadine-loratadine-if-not-available) (SNY)

Calendar months: [March 2026](https://sec-api.dev/fda-calendar/2026-03), [September 2026](https://sec-api.dev/fda-calendar/2026-09), [October 2028](https://sec-api.dev/fda-calendar/2028-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/linerixibat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Linerixibat PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/linerixibat

```bibtex
@misc{secapidev_pdufa_linerixibat_20261116,
  title        = {Linerixibat PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/linerixibat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_linerixibat_20261116","title":"Linerixibat PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/linerixibat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
